[Advances in Retinopathy of Prematurity]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Apr 28;41(2):261-266. doi: 10.3881/j.issn.1000-503X.10868.
[Article in Chinese]

Abstract

Retinopathy of prematurity(ROP)is a pathological neovascularization with fibrotic changes in the fundus of premature infants.It is a major cause of preventable blindness in children in both developing and developed countries.Treatment of ROP has long been a hot research topic in ophthalmology and pediatrics.With a clearer knowledge of the pathogenesis of ROP,more basic and clinical studies have been carried out.The anti-vascular endothelial growth factor therapy and surgical treatment have become mature strategies,and a variety of therapeutic drugs including insulin-like growth factor-1,transforming growth factor-β,polyunsaturated fatty acids,and β-adrenergic receptor blockers have been developed.This article reviews the recent advances in ROP.

Publication types

  • Review

MeSH terms

  • Child
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Neovascularization, Pathologic / therapy
  • Retinopathy of Prematurity / drug therapy*
  • Retinopathy of Prematurity / surgery*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Vascular Endothelial Growth Factor A